Academic literature on the topic 'Β1-Blockers'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Β1-Blockers.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Β1-Blockers":
Bennett, Miriam, Catherina L. Chang, Michael Tatley, Ruth Savage, and Robert J. Hancox. "The safety of cardioselective β1-blockers in asthma: literature review and search of global pharmacovigilance safety reports." ERJ Open Research 7, no. 1 (January 2021): 00801–2020. http://dx.doi.org/10.1183/23120541.00801-2020.
do Vale, Gabriel T., Carla S. Ceron, Natália A. Gonzaga, Janaina A. Simplicio, and Júlio C. Padovan. "Three Generations of β-blockers: History, Class Differences and Clinical Applicability." Current Hypertension Reviews 15, no. 1 (January 29, 2019): 22–31. http://dx.doi.org/10.2174/1573402114666180918102735.
Karoli, N. A., and A. P. Rebrov. "Possibilities and limitations of the use of beta-blockers in patients with cardiovascular disease and chronic obstructive pulmonary disease." Kardiologiia 61, no. 10 (October 30, 2021): 89–98. http://dx.doi.org/10.18087/cardio.2021.10.n1119.
Stănciulescu, Maria-Corina, Marius-Călin Popoiu, Anca Maria Cîmpean, Vlad-Laurentiu David, Rodica Heredea, Simona Cerbu, and Eugen-Sorin Boia. "Expression of β1 adrenergic receptor in vascular anomalies in children." Journal of International Medical Research 49, no. 9 (September 2021): 030006052110477. http://dx.doi.org/10.1177/03000605211047713.
Barcella, Carlo A., Talip E. Eroglu, Michiel Hulleman, Asger Granfeldt, Patrick C. Souverein, Grimur H. Mohr, Rudolph W. Koster, et al. "Association of beta-blockers and first-registered heart rhythm in out-of-hospital cardiac arrest: real-world data from population-based cohorts across two European countries." EP Europace 22, no. 8 (June 28, 2020): 1206–15. http://dx.doi.org/10.1093/europace/euaa124.
Grande, Fedora, Anna De Bartolo, Maria Antonietta Occhiuzzi, Anna Caruso, Carmine Rocca, Teresa Pasqua, Alessia Carocci, Vittoria Rago, Tommaso Angelone, and Maria Stefania Sinicropi. "Carbazole and Simplified Derivatives: Novel Tools toward β-Adrenergic Receptors Targeting." Applied Sciences 11, no. 12 (June 13, 2021): 5486. http://dx.doi.org/10.3390/app11125486.
Artym, Vira V., and Howard R. Petty. "Molecular Proximity of Kv1.3 Voltage-gated Potassium Channels and β1-Integrins on the Plasma Membrane of Melanoma Cells." Journal of General Physiology 120, no. 1 (June 10, 2002): 29–37. http://dx.doi.org/10.1085/jgp.20028607.
Singh, Bramah N. "β-Adrenergic Blockers as Antiarrhythmic and Antifibrillatory Compounds: An Overview." Journal of Cardiovascular Pharmacology and Therapeutics 10, no. 4_suppl (October 2005): S3—S14. http://dx.doi.org/10.1177/10742484050100i402.
Winther, K., and C. Hedman. "Beta-Adrenoceptor Blockade, Platelets, and Rheologic Factors." Cephalalgia 6, no. 5_suppl (May 1986): 33–40. http://dx.doi.org/10.1177/03331024860060s504.
Diniz, Gabriela Placoná, Marcela Sorelli Carneiro-Ramos, and Maria Luiza Morais Barreto-Chaves. "Thyroid Hormone Increases TGF-β1 in Cardiomyocytes Cultures Independently of Angiotensin II Type 1 and Type 2 Receptors." International Journal of Endocrinology 2010 (2010): 1–7. http://dx.doi.org/10.1155/2010/384890.
Dissertations / Theses on the topic "Β1-Blockers":
Bourcier, Camille. "Implication des pièges extracellulaires dans la neuro-inflammation induite par infection ou par traumatisme médullaire." Electronic Thesis or Diss., université Paris-Saclay, 2024. http://www.theses.fr/2024UPASQ005.
Whether triggered by infection or trauma, immune dysfunction can have serious consequences. Usually studied independently, these different origins may nevertheless involve common mechanisms. In the course of my thesis, I set out to study several of these mechanisms. One in particular caught my attention: the production of extracellular traps (ETs). To assess these possible interactions, I worked on two pathologies: sepsis, as an infectious factor, and spinal cord injury, as a factor of traumatic origin. Studies carried out after spinal cord injury enabled us to characterize the cell types producing ETs in this model. Studies carried out on two preclinical models of sepsis have enabled us to characterize and explore the effects of ETs on neuromuscular disorders in this pathology. These disorders can be alleviated by the administration of a specific inhibitor of ETs production, or by specific modulation of the adrenergic system, which has also been shown to reduce organ dysfunction and improve survival. This appears to be a promising therapeutic avenue which could be considered to improve the management of patients with excessive neuroinflammation
Hu, Hsin, and 胡馨. "β1-Adrenoceptor Genetic Polymorphisms and Other Predictors of the Tolerability and Response to β-Blockers in Patients with Heart Failure in Taiwan." Thesis, 2007. http://ndltd.ncl.edu.tw/handle/89650008662264541624.
國立臺灣大學
臨床藥學研究所
94
Background: The tolerated doses of β-blockers in Chinese heart failure (HF) patients were substantially lower than those wildly used in the Western countries, and the therapeutic response was heterogeneous. Although the mechanism responsible for the various tolerability and response was often attributed to β1-adrenoceptor (β1-AR) genetic polymorphisms at codon 49 and 389, their allele distribution was similar between Chinese and Caucasian, and β1-AR genetic full length sequencing has not been performed in Asian population. Objective: This study aimed to examine whether there are novel polymorphic loci in the β1-AR gene responsible for the difference in tolerability to β-blockers between Chinese and Caucasian HF patients, and to assess for other clinical predictors of tolerability and therapeutic response to β-blockers in Chinese population. Methods: We performed full length sequencing for β1-AR in 69 patients who had the diagnosis of chronic HF and were using, or have used, one of the three β-blockers carvedilol, metoprolol succinate, and bisoprolol. Clinical parameters including comorbidities, HF etiology, concurrent medication, left ventricular ejection fraction (LVEF) before the initiation and at the stable dose of β-blocker were retrieved from the medical records or inquiries into the patients. Results: Tolerated carvedilol stable dose was significantly different by HF etiology (p = 0.047). The stable dose of carvedilol for patients with dilated cardiomyopathy (DCMP) as the etiology of HF was higher than that of valvular heart disease (VHD) patients (14.589 ± 8.882 and 5.357 ± 7.594 mg/day, respectively, p = 0.018), and also tended to be higher than that of coronary artery disease (CAD) patients (9.544 ± 5.558 mg/day for CAD, p = 0.054). Multiple stepwise regression revealed that DCMP (B = 4.852, p = 0.007) was the only significant predictor of stable carvedilol dose; DCMP (B = 9.015, p = 0.011) and baseline LVEF (B = - 0.503, p < 0.001) appeared to be the significant predictors of LVEF improvement. In a subgroup analysis of 26 patients with CAD or DCMP (baseline LVEF≦35%), low-dose carvedilol (12.464 ± 7.977 mg / day) produced a significant improvement in LVEF (13.49 ± 16.66 %, p < 0.001). Neither novel variants other than the reported codon 49 and codon 389 within the coding region, nor correlation between β1-AR gene diplotypes and tolerability or response was found. The allele distributions of codon 49 and 389 were similar to those reported previously in the Chinese and Caucasian populations. Conclusion: Low-dose β-blocker therapy improved left ventricular function in Chinese patients with HF. Moreover, DCMP patients tolerated better to β-blocker, and those with DCMP as the etiology of HF or those had lower LVEF at baseline gained a greater improvement. For the β1-AR gene polymorphism, neither novel variant within the coding region, nor a different distribution pattern of alleles at codon 49 and codon 389 was noted.
Book chapters on the topic "Β1-Blockers":
Wang, Ting, Cai’e Wang, Hongyu Li, and Ran Wang. "Non-Selective Beta-Blockers in Patients with Cirrhosis: Current Evidence and Controversy." In Liver Cirrhosis - Advances in Diagnosis and Management [Working Title]. IntechOpen, 2024. http://dx.doi.org/10.5772/intechopen.1005683.
Conference papers on the topic "Β1-Blockers":
Kim, M., N. Baumlin, N. Silswal, J. S. Dennis, and M. A. Salathe. "Comparison of the Effectiveness of Angiotensin Receptor Blockers in Reversing TGF-β1-Induced CFTR and Mucociliary Dysfunction in Cystic Fibrosis Airway Epithelial Cells." In American Thoracic Society 2024 International Conference, May 17-22, 2024 - San Diego, CA. American Thoracic Society, 2024. http://dx.doi.org/10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6356.